Roswell Park’s early phase oncology research program is among the largest in New York State.

We offer a vast portfolio of options—accommodating all cancer types, for wherever the patient is in the spectrum of their disease—newly diagnosed, in remission, or facing recurrence.

What Sets Us Apart

- **Innovative new approaches** including angiogenesis inhibitors, novel targets and immunotherapies such as cancer vaccines, antibody therapy, cellular therapy and immune response modifiers.

- **Clinical Research Center**, a dedicated 7-bed, 10-chair clinical space to provide highest level of patient safety, monitoring and protocol adherence.

- **Streamlined evaluation process**. Within two weeks patients are seen by an oncologist from our team and presented with therapeutic options.

- **Lodging assistance** for out-of-town patients who need an affordable place to stay during their treatment.

- **On-site pharmacist** from the Investigational Drug Service to consult with patients, family members and staff as needed.

- **Collaboration with primary care team**. Your patient will remain your patient. Partnering with us allows access to options and resources that may impact your patient’s prognosis in a meaningful way.

www.roswellpark.org/partners-in-practice  

Partners In Practice  
medical information for physicians by physicians
Meet the Team

Igor Puzanov, MD, MSCI, FACP
Director, Early Phase Clinical Trials Program
Chief of Melanoma
Co-Leader, CCSG Experimental Therapeutics Program
Professor of Oncology, Department of Medicine

Kunle Odunsi, MD, PhD, FRCOG, FACOG
Deputy Director
Chair, Department of Gynecologic Oncology
The M. Steven Piver Professor of Gynecologic Oncology
Executive Director, Center for Immunotherapy
Co-Leader, Tumor Immunology and Immunotherapy Program

Marc Ernstoff, MD
Professor and Chair, Department of Medicine
Senior Vice President for Clinical Investigation
The Katherine Anne Gioia Chair of Medicine

Grace Dy, MD
Associate Professor of Oncology, Department of Medicine
Division Chief, Thoracic Oncology

Mateuz Opyrchal, MD, PhD
Assistant Professor of Oncology, Department of Medicine

Contact Us

Dawn DePaolo, RN, MSNL, CCRP
Clinical Research Administrator
716-845-3165

Patients may self-refer by calling 1-877-ASK-RPCI (1-877-275-7724).

Our Portfolio of Studies

Roswell Park’s Early Phase Clinical Trials involve the latest modalities and novel agents for all solid tumors.

A sampling of therapies available as a single agent or in combination with standard of care are listed below:

### Immunotherapy

- Anti-PD1
- Anti-PDL1
- Cancer Vaccines
- Cellular therapy
  - using patient’s own cells armed to fight their specific cancers
- Engineered T-Cell therapy

### Targeted Therapy

- ALK targeting
- Antibody drug conjugate
  - for all patients with cancers expressing C4.4a
- Anti CTLA4
- Carbazole Compound
  - that inhibits NF-κB and activates p53
- Histone deactelase inhibitor
- Notch receptor targeted antibody-drug conjugate against DLL
- PI3K/MTOR targeting
- SRC kinase and tubulin polymerization inhibitor

Our Portfolio of Studies

Roswell Park’s Early Phase Clinical Trials involve the latest modalities and novel agents for all solid tumors.

A sampling of therapies available as a single agent or in combination with standard of care are listed below: